HUMANA INC (HUM) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 0.18%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.18% | Share-based compensation / revenue. Period ending 2026-03-31. $243.00M ÷ $137.20B × 100 ≈ 0.18% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 137.20B USD | |
| Stock-based compensation | 243.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.44B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $137.20B | $243.00M | $2.44B | (m) | (m) | 0.18% | (m) | (m) |
| 2025-12-31 | (m) | $129.66B | $241.00M | $2.70B | (m) | (m) | 0.19% | (m) | (m) |
| 2025-09-30 | (m) | $126.36B | $247.00M | $2.97B | (m) | (m) | 0.20% | (m) | (m) |
| 2025-06-30 | (m) | $123.11B | $217.00M | $3.30B | (m) | (m) | 0.18% | (m) | (m) |
| 2025-03-31 | (m) | $120.26B | $211.00M | $3.34B | (m) | (m) | 0.18% | (m) | (m) |
| 2024-12-31 | (m) | $117.76B | $207.00M | $2.56B | (m) | (m) | 0.18% | (m) | (m) |
| 2024-09-30 | (m) | $115.01B | $186.00M | $2.76B | (m) | (m) | 0.16% | (m) | (m) |
| 2024-06-30 | (m) | $112.04B | $186.00M | $3.23B | (m) | (m) | 0.17% | (m) | (m) |
| 2024-03-31 | (m) | $109.24B | $182.00M | $3.53B | $539.00M | (m) | 0.17% | 6.55× | Reported |
| 2023-12-31 | (m) | $106.37B | $175.00M | $4.01B | $493.00M | (m) | 0.16% | 8.14× | Reported |
| 2023-09-30 | (m) | $102.35B | $185.00M | $4.49B | $455.00M | (m) | 0.18% | 9.86× | Reported |
| 2023-06-30 | (m) | $98.73B | $212.00M | $4.45B | $443.00M | (m) | 0.21% | 10.05× | Reported |
| 2023-03-31 | (m) | $95.64B | $211.00M | $4.23B | $424.00M | (m) | 0.22% | 9.98× | Reported |
| 2022-12-31 | (m) | $92.87B | $216.00M | $3.80B | $401.00M | (m) | 0.23% | 9.48× | Reported |
| 2022-09-30 | (m) | $91.48B | $221.00M | $3.74B | $384.00M | (m) | 0.24% | 9.73× | Reported |
| 2022-06-30 | (m) | $89.38B | $189.00M | $3.19B | $370.00M | (m) | 0.21% | 8.63× | Reported |
| 2022-03-31 | (m) | $86.37B | $184.00M | $3.21B | $348.00M | (m) | 0.21% | 9.24× | Reported |
| 2021-12-31 | (m) | $83.06B | $180.00M | $3.15B | $326.00M | (m) | 0.22% | 9.66× | Reported |
| 2021-09-30 | (m) | $81.07B | $184.00M | $2.74B | $307.00M | (m) | 0.23% | 8.93× | Reported |
| 2021-06-30 | (m) | $80.45B | $183.00M | $3.94B | $294.00M | (m) | 0.23% | 13.39× | Reported |
| 2021-03-31 | (m) | $78.89B | $184.00M | $5.13B | $291.00M | (m) | 0.23% | 17.65× | Reported |
| 2020-12-31 | (m) | $77.16B | $181.00M | $4.99B | $283.00M | (m) | 0.23% | 17.62× | Reported |
| 2020-09-30 | (m) | $74.39B | $173.00M | $5.69B | $269.00M | (m) | 0.23% | 21.17× | Reported |
| 2020-06-30 | (m) | $70.55B | $169.00M | $4.74B | $256.00M | (m) | 0.24% | 18.51× | Reported |
| 2020-03-31 | (m) | $67.72B | $166.00M | $3.42B | $240.00M | (m) | 0.25% | 14.25× | Reported |
| 2019-12-31 | (m) | $64.89B | $163.00M | $3.19B | $242.00M | (m) | 0.25% | 13.19× | Reported |
| 2019-09-30 | (m) | $62.76B | $151.00M | $3.35B | $243.00M | (m) | 0.24% | 13.77× | Reported |
| 2019-06-30 | (m) | $60.73B | $144.00M | $3.44B | $234.00M | (m) | 0.24% | 14.70× | Reported |
| 2019-03-31 | (m) | (m) | $135.00M | $3.19B | $227.00M | (m) | (m) | 14.04× | Reported |
| 2018-12-31 | (m) | $56.91B | $137.00M | $3.10B | $218.00M | (m) | 0.24% | 14.22× | Reported |
| 2018-09-30 | (m) | (m) | $146.00M | $3.15B | $235.00M | (m) | (m) | 13.40× | Reported |
| 2018-06-30 | (m) | (m) | $143.00M | $3.05B | $241.00M | (m) | (m) | 12.64× | Reported |
| 2018-03-31 | (m) | (m) | $166.00M | $3.28B | $246.00M | (m) | (m) | 13.35× | Reported |
| 2017-12-31 | (m) | (m) | $157.00M | $4.26B | $242.00M | (m) | (m) | 17.61× | Reported |
| 2017-09-30 | (m) | (m) | $155.00M | $3.26B | $214.00M | (m) | (m) | 15.22× | Reported |
| 2017-06-30 | (m) | (m) | $150.00M | $3.35B | $202.00M | (m) | (m) | 16.58× | Reported |
| 2017-03-31 | (m) | (m) | $118.00M | $2.93B | $191.00M | (m) | (m) | 15.35× | Reported |
| 2016-12-31 | (m) | (m) | $115.00M | $1.74B | $189.00M | (m) | (m) | 9.21× | Reported |
| 2016-09-30 | (m) | (m) | $93.00M | $2.47B | $187.00M | (m) | (m) | 13.20× | Reported |
| 2016-06-30 | (m) | (m) | $88.00M | $2.21B | $187.00M | (m) | (m) | 11.84× | Reported |
| 2016-03-31 | (m) | (m) | $88.00M | $2.10B | $187.00M | (m) | (m) | 11.25× | Reported |
| 2015-12-31 | (m) | (m) | $109.00M | $2.35B | $186.00M | (m) | (m) | 12.62× | Reported |
| 2015-09-30 | (m) | (m) | $114.00M | $2.43B | $224.00M | (m) | (m) | 10.84× | Reported |
| 2015-06-30 | (m) | (m) | $112.00M | $2.32B | $215.00M | (m) | (m) | 10.80× | Reported |
| 2015-03-31 | (m) | (m) | $109.00M | $2.43B | $203.00M | (m) | (m) | 11.98× | Reported |
| 2014-12-31 | (m) | (m) | $98.00M | $2.36B | $192.00M | (m) | (m) | 12.30× | Reported |
| 2014-09-30 | (m) | (m) | $95.00M | $1.98B | $143.00M | (m) | (m) | 13.83× | Reported |
| 2014-06-30 | (m) | (m) | $96.00M | $2.01B | $140.00M | (m) | (m) | 14.35× | Reported |
| 2014-03-31 | (m) | (m) | $93.00M | $2.02B | $140.00M | (m) | (m) | 14.41× | Reported |
| 2013-12-31 | (m) | (m) | $92.00M | $2.06B | $140.00M | (m) | (m) | 14.72× | Reported |
| 2013-09-30 | (m) | (m) | $87.00M | $2.38B | $132.00M | (m) | (m) | 18.06× | Reported |
| 2013-06-30 | (m) | $40.02B | $79.00M | $2.46B | $123.00M | (m) | 0.20% | 20.03× | Reported |
| 2013-03-31 | (m) | $39.39B | $74.00M | $2.37B | $114.00M | (m) | 0.19% | 20.75× | Reported |
| 2012-12-31 | (m) | $39.13B | $82.00M | $2.02B | $105.00M | (m) | 0.21% | 19.20× | Reported |
| 2012-09-30 | (m) | $38.63B | $82.00M | $2.05B | $105.00M | (m) | 0.21% | 19.50× | Reported |
| 2012-06-30 | (m) | $38.27B | $80.00M | $2.07B | $106.00M | (m) | 0.21% | 19.55× | Reported |
| 2012-03-31 | (m) | $37.86B | $77.00M | $2.24B | $108.00M | (m) | 0.20% | 20.70× | Reported |
| 2011-12-31 | (m) | $36.83B | $67.00M | $2.34B | $109.00M | (m) | 0.18% | 21.50× | Reported |
| 2011-09-30 | (m) | $36.05B | $63.62M | $2.20B | $108.34M | (m) | 0.18% | 20.35× | Reported |
| 2011-06-30 | (m) | $35.37B | $64.30M | $2.13B | $107.42M | (m) | 0.18% | 19.81× | Reported |
| 2011-03-31 | (m) | $34.68B | $65.38M | $1.94B | $105.97M | (m) | 0.19% | 18.26× | Reported |
| 2010-12-31 | (m) | $33.87B | $62.95M | $1.85B | $105.06M | (m) | 0.19% | 17.65× | Reported |
| 2010-09-30 | (m) | $33.15B | $69.16M | $2.08B | $104.92M | (m) | 0.21% | 19.81× | Reported |
| 2010-06-30 | (m) | $32.44B | $72.47M | $1.93B | $105.03M | (m) | 0.22% | 18.34× | Reported |
| 2010-03-31 | (m) | $31.69B | $77.53M | $1.83B | $105.39M | (m) | 0.24% | 17.37× | Reported |
| 2009-12-31 | (m) | $30.96B | $65.87M | $1.71B | $105.84M | (m) | 0.21% | 16.13× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $28.95B | $55.37M | $1.07B | $80.29M | (m) | 0.19% | 13.37× | Reported |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $25.29B | $42.13M | $1.36B | $68.88M | (m) | 0.17% | 19.72× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CENTENE CORP (CNC) | United States | $30.588B | -6.22 |
| Cigna Group (CI) | United States | $70.160B | 10.44 |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| Elevance Health, Inc. (ELV) | United States | $86.364B | 16.90 |
| Alignment Healthcare, Inc. (ALHC) | United States | $1.593B | 121.28 |
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |